Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin: The Receptor and Signaling Pathways

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR.

Nature communications·2026

Same author

Noncanonical functions of UGT2B17 promote castration-resistant prostate cancer progression.

The Journal of clinical investigation·2025

Same author

Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025

Same author

Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.

Oncogene·2025

Same author

Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional Cohorts.

European urology oncology·2025

Same author

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Insulin receptor expression by human prostate cancers.

Michael E Cox¹, Martin E Gleave, Mahvash Zakikhani

¹The Prostate Center at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

|September 12, 2008

Summary

Insulin receptors are present on prostate cancer cells, with higher expression on malignant tissues compared to benign ones. This finding is crucial for understanding prostate cancer growth and developing targeted therapies.

More Related Videos

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Experiment Videos

Last Updated: Jul 1, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Area of Science:

Oncology
Endocrinology
Molecular Biology

Background:

Emerging evidence suggests prostate cancer may respond to insulin.
Knowledge regarding insulin receptor expression on prostate tissue is limited.

Purpose of the Study:

To investigate the expression of insulin receptors on benign and malignant prostate tissues.
To explore the presence of insulin receptor isoforms and their co-expression with IGF-I receptors in prostate cancer.

Main Methods:

Immunohistochemical staining of 644 prostate tissue cores (benign and malignant) using antibodies for insulin-like growth factor I receptor and insulin receptor.
Analysis of public gene expression databases.
Reverse transcription polymerase chain reaction (RT-PCR) to detect insulin receptor isoforms.

Main Results:

Immunoreactivity confirmed the presence of insulin receptors, IGF-I receptors, and hybrid receptors.
Insulin receptor staining intensity was significantly higher in malignant prostate epithelial cells (P < 0.001).
Co-expression of insulin receptor and IGF-I receptor mRNA is common in prostate cancer; both IR-A and IR-B isoforms are present.

Conclusions:

This study documents the presence of insulin receptors on primary human prostate cancers.
Findings support the relevance of targeting insulin and IGF-I receptors in ongoing clinical trials.
Results contribute to understanding the link between obesity-associated hyperinsulinemia and prostate cancer prognosis.